Soh-ichi Sugitani

Suggest Changes
Learn More
BACKGROUND/AIMS To clarify clinical parameters predicting sustained viral response (SVR) during 48 weeks pegylated-interferon (peg-IFN)alpha-2b plus ribavirin therapy for Japanese patients with(More)
  • 1